Daval International Limited is a privately owned, UK registered biopharmaceutical company with over 1,500 shareholders. The company was formed in 2000 and has been dedicated to the development of AIMSPRO and Ceremben. Daval has been awarded SME and EIS status under the EMA and HMRC criteria, respectively. Daval continues to be funded by investors as well as through revenue generated from the Named Patient/Special Access programmes that allow doctors in certain countries to prescribe the drugs on a "compassionate use" basis. The funds are used primarily to meet the costs of ongoing research and development (the majority of which is outsourced) and in particular to finance the existing clinical trials, which are now nearing completion. Daval will continue to strive to satisfy all stakeholders, but the overriding objective is to guide AIMSPRO through a successful development path, obtain regulatory approval and provide true benefit to the millions of people suffering from the diseases where AIMSPRO has shown initial evidence of providing a positive effect.
Manufacturing of the products is completely outsourced, with the entire product supply chain (serum sourcing, product processing, transportation, storage and distribution) being operated by Daval’s preferred supply chain partners, in strict accordance to GMP guidelines.